USA flag logo/image

An Official Website of the United States Government

Acute Coronary Syndrome animal model

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43HL116052
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
VASADE BIOSCIENCES, INC.
675 US Highway One North Brunswick, NJ 08902-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Acute Coronary Syndrome animal model
Agency: HHS
Contract: 1R43HL116052-01
Award Amount: $167,930.00
 

Abstract:

DESCRIPTION (provided by applicant): Most new therapeutic measures that protect infarct size in experimental animals have failed in the clinics, to a large extent because they are only effective when administered prior to coronary artery occlusion. Our preliminary data indicate that an adenylyl cyclase type 5 (AC5) inhibitor, vidarabine (also known as Ara-A, AraAde, and Vira-A) appears to reduce infarct size when administered after coronary artery reperfusion (see preliminary data). This drug, which is already FDA approved, as an antiviral compound, will be potentially useful for patients with myocardial infarction (MI), who undergo reperfusion therapy. Even more important, this drug will be useful in the setting of acute coronary syndrome, which is becomingincreasingly prevalent1 and despite current advances, the mortality of acute coronary syndrome remains high2. Acute coronary syndrome encompasses a broad spectrum of clinical conditions consistent with acute myocardial infarction (AMI) or angina and accounts for 1.36 million hospitalizations a year. The key feature of acute coronary syndrome is that the patients develop ischemic episodes giving the physician warning of an impending MI, making the use of an agent that reduces infarct size after MI extremelyuseful, particularly one that is effective following a preceding ischemic event. In phase I we will focus on determining the extent to which AC5 inhibitor protects infarct size when administered either after coronary artery reperfusion following coronaryocclusion in a heart virgin to ischemia, in the post ischemic setting after a 15 minute (sentinel) coronary occlusion which induces a small infarct followed by a longer period of test ischemia at 8 hours after the initial ischemic insult, at a time when neithr first nor second window ischemic preconditioning is active, and AC5 inhibitor administration after the prolonged 30 minute ischemic event. Once Aims 1and 2 have been completed, in phase II we propose to test AC5 inhibition for acute coronary syndromein a pig model for efficacy and safety, and if the results are positive we will move to a clinical trial, since the drg is already FDA approved. PUBLIC HEALTH RELEVANCE: According to the 2009 AHA heart disease and stroke statistics it has been estimated that 1 out of every 5 deaths in the United States is caused by coronary heart disease and myocardial infarction. The current proposal will develop a drug, already FDA approved, that can be given to patients with acute myocardial infarction as well as to those with acute coronary syndrome. Acute coronary syndrome encompasses a broad spectrum of clinical conditions consistent with acute myocardial infarction and accounts for 1.36 million hospitalizations a year.

Principal Investigator:

Patricio Abarzua
609-618-0565
abarzua@vasadebiosciences.com

Business Contact:

Vatner F. Stephen
609-618-0565
vatner@vasadebiosciences.com
Small Business Information at Submission:

VASADE BIOSCIENCES, INC.
675 US Highway One North Brunswick, NJ 08902-

EIN/Tax ID: 132011528
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No